<DOC>
	<DOC>NCT01336738</DOC>
	<brief_summary>B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months. One of the treatments will be sitagliptin which is an approved drug, and another treatment will be placebo, which does not contain active ingredient.</brief_summary>
	<brief_title>Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Subjects with type 2 diabetes on stable doses of background medicines for management of diabetes; aged 1870 years; body mass index between 22.5 and 45.5 kg/m2 Subjects with type 1 diabetes, heart attack or stroke in the past 6 months, uncontrolled blood pressure, significant kidney disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>safety and efficacy study with PF-04991532</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>